gallop: The US adult obesity rate will reach an all-time high of 39.9% in 2022. Gradually decreases to 37.0% in 2025. This is a statistically significant decrease, with the number of obese adults decreasing by approximately 7.6 million compared to three years ago. Meanwhile, the diagnosis rate of diabetes, a lifelong disease that can be managed but cannot be cured, is currently at 13.8%, the highest ever. Both indicators are part of the ongoing Gallup National Health and Well-Being Index.
(…) Over the past year, more Americans have chosen GLP-1 drugs to treat type 2 diabetes, such as semaglutide (brand names Ozempic and Wegovy), for weight loss purposes. Specifically, the percentage of adults who reported taking this class of medication for weight loss increased to 12.4%, compared to 5.8% in February 2024, when Gallup first measured it. Although usage among women (15.2%) continues to outpace men (9.7%), both groups have more than doubled their usage over the past year. These results are consistent with a national increase in awareness of medications used for weight loss from 80% to 89% over the same period.
